SOX chemotherapy plus immunotherapy for junction stomach-esophagus cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed esophagogastric junction adenocarcinoma that is stage cT3-4a, has lymph node involvement (N+), and has no distant spread (M0)
- You must be able to give signed consent and agree to share tumor tissue from a biopsy or surgery for PD-L1, EBV, and MSI testing
- You must be age 18–75 and able to have the planned surgery (your health must allow abdominal and/or chest surgery)
- Your blood counts and organ tests must be in safe ranges (for example, platelets and white blood cells must be high enough, and liver/kidney/clotting tests must be within limits)
- You must have good general function (ECOG 0–1) and expected survival of at least 6 months
- If you can become pregnant or are able to father a child, you must use effective birth control during treatment and for 6 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests giving immunotherapy together with chemotherapy before surgery for certain “locally advanced” cancers at the esophagus-stomach junction. It may help shrink the tumor and improve outcomes by treating the cancer earlier with both immune and chemotherapy approaches.
This trial studies giving immunotherapy together with chemotherapy and radiation before surgery for esophagogastric junction cancer. It aims to shrink the tumor and improve outcomes for people with early locally advanced, HER2-negative disease.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
This trial tests a combination of three drugs—tislelizumab (immunotherapy), anlotinib (targeted therapy), and a chemotherapy regimen (S1 plus oxaliplatin)—given before surgery for locally advanced adenocarcinoma of the gastroesophageal junction. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.